Windlas Biotech Pvt Ltd, a leading Indian pharmaceutical contract drug development and manufacturing organisation, in partnership with Mateon Therapeutics, Inc, a US-based oncology company focusing on TGF-β inhibitors as therapies against cancers and infectious diseases, launched a first-of-its-kind integrated solution for respiratory wellness in India.

The product, PulmoHeal™ is a broad-spectrum, lung therapy food supplement that is supported by a multi-centre rigorous clinical study and integrated with its own telemedicine AI based platform to offer continuous 360 care for patients in India.

Developed from extract of indigenous plant Artemisia, the active component of PulmoHealTM, Artemisinin, has been known to exhibit multiple pharmacological activity against inflammation, viral infections, and lung repair. Available on online channels, Amazon, Flipkart and 1mg.com from February 28.

The combined drug + AI telemedicine 360 solution is being launched to transform respiratory illness.

Hitesh Windlass, MD, Windlas Biotech, commented, "PulmoHealTM is a unique combination of cutting-edge manufacturing, clinical drug development, and artificial intelligence (AI), which harnesses the power of traditional and modern science. The ARTIHealthTM model can be replicated for a range of therapies including monitoring COVID-19 infection.”

Saran Saund, CBO, Mateon, commented, “We are optimistic that our solution will be beneficial even beyond current pandemic by empowering the patients and reducing burden on health care providers.”

Dr Vuong Trieu, CEO and Chairman, Mateon said, "We are pleased to be able to leverage on the deep tradition of Indian medicine and advance artificial intelligence & supercomputing technologies under one umbrella to create this innovative solution to healthcare, one which we hope to replicate throughout the world across multiple indications.”